According to research by Germany Trade and Invest (GTAI), Germany is one of the world’s top 5 leading locations for clinical studies, with its most important indication areas including oncology, diabetes, and inflammatory, cardiovascular and infectious diseases. The country has proven to be a desirable location for clinical research, not only due to its population size of over 83 million but also because of its strong healthcare infrastructure.
In 2020, there were more than 2,000 clinical studies in Germany, including those in the following locations:
North Rhine-Westphalia: 401 clinical studies
Baden-Wurttemberg: 328 clinical studies
Bavaria: 266 clinical studies
Berlin: 259 clinical studies
Saxony: 200 clinical studies
Hamburg: 157 clinical studies
Hessen: 151 clinical studies
Niedersachsen: 133 clinical studies
Schleswig-Holstein: 113 clinical studies
Saarland: 78 clinical studies
Rhineland-Palatinate: 78 clinical studies
Thuringia: 35 clinical studies
Saxony-Anhalt: 27 clinical studies
In October 2020, there were also 97 COVID-19 clinical studies registered at sites in Germany, around 50% of which were international collaborations, highlighting the country’s leading role in clinical research not only in Europe, but across the globe.
PharmiWeb.Jobs is launching in Germany! Click here for more information or get in touch with PharmiWeb’s sales team on +44 (0)845 5651771 or by emailing email@example.com – we look forward to hearing from you!